CinnaGen Reports Results Of ReciGen For COVID-19

Interferon Beta-1a In Combination Therapy For COVID-19 Pneumonia

 
• By Dean Rudge

CinnaGen has revealed clinical trial results suggesting that its ReciGen interferon beta-1a product in combination with concomitant antiviral therapy can be “a new safe and effective” treatment option for COVID-19 patients, “critical for the expected second wave of the pandemic.”

Tehran
CinnaGen has also a nasal formulation of interferon beta 1a under investigation • Source: Shutterstock

Iranian biotech CinnaGen has unveiled positive results from the firm’s clinical studies trialing its ReciGen (interferon beta-1a) multiple-sclerosis as a treatment option to reduce COVID-19 symptoms.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin